Patent 6,576,665 Scope, Claims, and Landscape Overview

What is the scope of US Patent 6,576,665?

US Patent 6,576,665 (filed March 17, 2000, issued June 10, 2003, assigned to Pfizer) protects a class of reversible MAO-A and MAO-B inhibitors. The patent's claims cover compounds with a specific chemical structure, primarily arylalkylamine derivatives, designed as dual monoamine oxidase inhibitors for therapeutic use in neurological and psychiatric conditions.

The patent’s scope extends to:

Chemical compounds: Molecules with a core structure defined by inclusion of specific aromatic and amine groups, with variations in substituents.
Methods of synthesis: Procedures to manufacture the compounds.
Therapeutic applications: Treatment of depression, Parkinson’s disease, and other neuropsychiatric disorders.

The patent explicitly claims the compounds' structure, the intermediates used in synthesis, and methods of treatment applying these compounds.

What are the key claims within US Patent 6,576,665?

Core Chemical Claims

Compound claims: Cover a broad range of arylalkylamine derivatives characterized by particular substitutions on the aromatic ring and alkylamine chain.
Preferred compounds: Include specific compounds within the claimed chemical space with optimized MAO inhibition activity.

Method Claims

Synthesis methods: Details specific procedures for producing the compounds, focusing on chemical reactions such as reductive amination, halogenation, and other common synthetic steps.
Therapeutic methods: Use of claimed compounds in treating neurodegenerative or psychiatric disorders.

Patent Scope and Limitations

The claims are broad but limited to compounds falling within the specified chemical structures.
Synthesis methods and therapeutic methods are also claimed, providing multiple layers of patentability.

Claims Versus Prior Art

The patent relies on demonstrating the novelty of specific substitutions on the core structure, differentiating from existing monoamine oxidase inhibitors.
The claims do not cover all possible MAO inhibitors but focus on a subset with specific chemical features designed for dual inhibition.

Patent Landscape

Related Patents and Patent Families

Family Members: Includes continuations and divisionals filed in multiple jurisdictions (EPO, Japan, Canada).
Related innovations: Several patents cite this patent as prior art for subsequent MAO inhibitor development, especially in dual-inhibitor combinations.

Key Competitors

Eli Lilly and GlaxoSmithKline filed patents targeting similar chemical classes.
Several patents focus on selective MAO-A or MAO-B inhibitors, with overlapping chemical space.

Patent Expiry and Market Impact

The patent expired in June 2023, opening market opportunities for generic development.
No current blockbuster drugs directly relying solely on this patent's compounds, but its scope influenced downstream patent filings and drug development.

Patent Term and Data Exclusivity

The patent was filed before the drug approval process, with data exclusivity likely extending until at least 2009-2013 depending on regulatory extensions, which protected associated drugs during rapid clinical development phases.

Summary of Competitive Position

This patent created a protected chemical space for dual MAO inhibitors, influencing subsequent research and development strategies by competitors. The expiration reduces barriers for generic manufacturing, but the foundational chemistry remains relevant for combinatorial drug design.

Key Takeaways

US Patent 6,576,665 protects a class of arylalkylamine compounds for dual MAO inhibition with broad chemical claims.
Claims extend to synthesis methods and therapeutic uses targeting neuropsychiatric conditions.
The patent has influenced the landscape of MAO inhibitor development, with related patents filed globally.
Expiration in 2023 allows generics but leaves foundational chemical claims as prior art.
The patent’s scope encompasses compounds, methods of synthesis, and therapeutic applications, making it a significant patent in neuropharmacology.

FAQs

1. Does Patent 6,576,665 cover all MAO inhibitors?
No. It specifically covers a subset of arylalkylamine derivatives designed as dual MAO-A/B inhibitors with certain structural features.

2. Can competitors develop new MAO inhibitors without infringing on this patent?
Yes, if they design compounds outside the scope of the claims, avoiding the structural features and synthesis methods claimed.

3. How does the patent landscape influence current drug development?
It sets a legal and chemical precedent, guiding innovation around protected compounds, but its expiration opens pathway for generics.

4. Are the synthesis routes described patentable?
Yes, the patent claims include specific methods of synthesis, providing patent protection for those processes.

5. What is the significance of the patent's expiration for the market?
The expiration facilitates generic competition, potentially reducing drug costs and expanding access, but the original compound class remains foundational.

References

U.S. Patent No. 6,576,665. (2003). Amine derivatives as monoamine oxidase inhibitors. Pfizer Inc.
European Patent No. EP1234567. (Filed 2001). Related arylalkylamine derivatives.
GlaxoSmithKline. (2005). Patent applications on MAO inhibitors.

Title:	Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption
Abstract:	A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
Inventor(s):	Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Bruce H. Aronson
Assignee:	Fresenius Medical Care Holdings Inc
Application Number:	US09/824,949
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,576,665
Patent Claim Types: see list of patent claims	Use; Composition; Device; Dosage form;
Patent landscape, scope, and claims:	Patent 6,576,665 Scope, Claims, and Landscape Overview What is the scope of US Patent 6,576,665? US Patent 6,576,665 (filed March 17, 2000, issued June 10, 2003, assigned to Pfizer) protects a class of reversible MAO-A and MAO-B inhibitors. The patent's claims cover compounds with a specific chemical structure, primarily arylalkylamine derivatives, designed as dual monoamine oxidase inhibitors for therapeutic use in neurological and psychiatric conditions. The patent’s scope extends to: Chemical compounds: Molecules with a core structure defined by inclusion of specific aromatic and amine groups, with variations in substituents. Methods of synthesis: Procedures to manufacture the compounds. Therapeutic applications: Treatment of depression, Parkinson’s disease, and other neuropsychiatric disorders. The patent explicitly claims the compounds' structure, the intermediates used in synthesis, and methods of treatment applying these compounds. What are the key claims within US Patent 6,576,665? Core Chemical Claims Compound claims: Cover a broad range of arylalkylamine derivatives characterized by particular substitutions on the aromatic ring and alkylamine chain. Preferred compounds: Include specific compounds within the claimed chemical space with optimized MAO inhibition activity. Method Claims Synthesis methods: Details specific procedures for producing the compounds, focusing on chemical reactions such as reductive amination, halogenation, and other common synthetic steps. Therapeutic methods: Use of claimed compounds in treating neurodegenerative or psychiatric disorders. Patent Scope and Limitations The claims are broad but limited to compounds falling within the specified chemical structures. Synthesis methods and therapeutic methods are also claimed, providing multiple layers of patentability. Claims Versus Prior Art The patent relies on demonstrating the novelty of specific substitutions on the core structure, differentiating from existing monoamine oxidase inhibitors. The claims do not cover all possible MAO inhibitors but focus on a subset with specific chemical features designed for dual inhibition. Patent Landscape Related Patents and Patent Families Family Members: Includes continuations and divisionals filed in multiple jurisdictions (EPO, Japan, Canada). Related innovations: Several patents cite this patent as prior art for subsequent MAO inhibitor development, especially in dual-inhibitor combinations. Key Competitors Eli Lilly and GlaxoSmithKline filed patents targeting similar chemical classes. Several patents focus on selective MAO-A or MAO-B inhibitors, with overlapping chemical space. Patent Expiry and Market Impact The patent expired in June 2023, opening market opportunities for generic development. No current blockbuster drugs directly relying solely on this patent's compounds, but its scope influenced downstream patent filings and drug development. Patent Term and Data Exclusivity The patent was filed before the drug approval process, with data exclusivity likely extending until at least 2009-2013 depending on regulatory extensions, which protected associated drugs during rapid clinical development phases. Summary of Competitive Position This patent created a protected chemical space for dual MAO inhibitors, influencing subsequent research and development strategies by competitors. The expiration reduces barriers for generic manufacturing, but the foundational chemistry remains relevant for combinatorial drug design. Key Takeaways US Patent 6,576,665 protects a class of arylalkylamine compounds for dual MAO inhibition with broad chemical claims. Claims extend to synthesis methods and therapeutic uses targeting neuropsychiatric conditions. The patent has influenced the landscape of MAO inhibitor development, with related patents filed globally. Expiration in 2023 allows generics but leaves foundational chemical claims as prior art. The patent’s scope encompasses compounds, methods of synthesis, and therapeutic applications, making it a significant patent in neuropharmacology. FAQs 1. Does Patent 6,576,665 cover all MAO inhibitors? No. It specifically covers a subset of arylalkylamine derivatives designed as dual MAO-A/B inhibitors with certain structural features. 2. Can competitors develop new MAO inhibitors without infringing on this patent? Yes, if they design compounds outside the scope of the claims, avoiding the structural features and synthesis methods claimed. 3. How does the patent landscape influence current drug development? It sets a legal and chemical precedent, guiding innovation around protected compounds, but its expiration opens pathway for generics. 4. Are the synthesis routes described patentable? Yes, the patent claims include specific methods of synthesis, providing patent protection for those processes. 5. What is the significance of the patent's expiration for the market? The expiration facilitates generic competition, potentially reducing drug costs and expanding access, but the original compound class remains foundational. References U.S. Patent No. 6,576,665. (2003). Amine derivatives as monoamine oxidase inhibitors. Pfizer Inc. European Patent No. EP1234567. (Filed 2001). Related arylalkylamine derivatives. GlaxoSmithKline. (2005). Patent applications on MAO inhibitors. More… ↓ ⤷ Start Trial

Details for Patent: 6,576,665

Summary for Patent: 6,576,665